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Since the recognition of basic fibroblast growth factor(bFGF, FGF-2) and acidic FGF (aFGF, FGF-1) asproliferation and maintenance factors for endothelial
cells in culture,1,2 much interest has arisen regarding their role
as potential angiogenic factors in tumors and tissue healing in
vivo. The FGFs, of which presently at least 22 members have
been recognized,3 interact with FGF receptors (FGFRs). After
FGF binding, the FGFRs dimerize and become activated
displaying protein tyrosine kinase activity and subsequent
signaling in the cell.4,5 Four functional FGFRs have been
recognized, FGFR1–4, most of which can be encountered in
various alternative spliced isoforms. FGFR1 plays an essen-
tial role during early stages of development of the mesoderm
and at several levels during organogenesis.3,6 FGF/FGFR1 is
expressed almost exclusively in the mesenchyme, including
endothelial cells, smooth muscle cells, and hemopoietic
progenitor cells. FGFR1 is involved in the stimulation and
proliferation of endothelial cells and vascularization by FGFs,
particularly bFGF and aFGF. FGFs also promote the forma-
tion of hematopoietic progenitor cells in early development,
which requires the FGFR1 as well.7,8 In line with this,
chromosomal translocation involving FGFR1 has been ob-
served in patients with stem-cell myeloproliferative disease,
probably caused by constitutive activation of the FGFR1
gene.9
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It has long been anticipated that hematopoietic progenitor
cells and endothelial progenitor cells derive from a common
cell type, the hemangioblast.10 Studies on mouse embryos
have shown that such hemangioblast cells indeed exist. These
cells develop in the primitive streak of the embryo and
migrate to the yolk sac, where they form blood islands.11 The
outer cells of these blood islands mature into endothelial cells
and form a vascular plexus, while the inner cells develop into
primitive and definitive hematopoietic progenitor cells and
their subsequent lineages of blood cells. In addition, in the
para-aortic splanchnopleura, hemangioblasts develop into
vascular structures.11 Later in development the primitive and
definitive hematopoietic progenitor (“stem”) cells migrate to
the fetal liver and subsequently to the bone marrow, where
they remain life-long active as a source for white and red
blood cells, mast cells, and megakaryocytes, from which
blood platelets are formed.
One of the issues that remained unresolved was the
contribution of FGF signaling to the early development of the
vascular tree. Embryos deficient in FGFR1 stop growing at an
early stage of gestation because of abnormal mesodermal
patterning.12,13 However, when embryonic stem cells were
derived from FGFR1-deficient blastocysts and administered
subcutaneously in nude mice, these embryonic stem cells
were still able to differentiate into different types of meso-
dermal cells.14 Thus FGFR1 causes inappropriate mesoder-
mal patterning rather than impeding mesodermal differentia-
tion. Because FGFs are required for proper mesodermal
pattern development, deficiency of FGFR1 interfered with the
early development and viability of embryos in the mouse. To
overcome this initial blockade of development, Faloon et al7
and Magnusson et al15,16 used the technique of growing
embryoid bodies from embryonic stem cells. Pluripotent
embryonic stem cells can be isolated from the inner cell mass
of a blastula stage embryo. These cells can be grown in
culture and can be induced to aggregate into spheroid bodies,
the embryoid bodies, by specific culture conditions, which
includes the withdrawal of the factor LIF. The inner mass of
these embryoid bodies subsequently develops into mesoder-
mal cells, a part of which further differentiate into heman-
gioblast cells and subsequently into hematopoietic cells,
endothelial cells, and vascular smooth muscle cells (Figure
1). The embryoid bodies appeared helpful in elucidating the
contribution of various factors involved in hematopoietic and
endothelial development.17–19 Their regulation is highly com-
parable with that in the yolk sac of murine embryos. It has
become clear that the differentiation steps from mesodermal
progenitor cells into hemangioblasts and subsequently into
primitive and definitive lineages of hematopoietic and endo-
thelial progenitor cells required the expression of growth
factors including BMP-4 and VEGF, the growth factor
receptors VEGFR-2 (Flk1, KDR) and FGFR1, CD41, and
transcription factors, such as SCL/Tal1 and Runx1 (required
for hematopoietic cells formation).20–29 Members of the
transforming growth factor (TGF)- signaling family, activin
A, TGF-, and possibly BMP-2, act as positive (Activin A)
and negative regulators (TGF-).30,21 The various steps
thought to be involved in the differentiation of mesoderm into
hematopoietic and endothelial progenitor cells are summa-
rized in Figure 2.
In this issue of Arteriosclerosis, Thrombosis, and Vascular
Biology, Magnusson et al15 report on the expression of
FGFR-1 in embryoid bodies and its requirement for hemato-
poietic and endothelial cell development and function. They
show that FGFR1 is expressed and becomes activated in a
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subpopulation of endothelial cells during the development of
embryoid bodies. Its expression was associated with cell
division, suggesting that particularly dividing endothelial
cells express FGFR1. Whether this is related to the cell cycle
state of the cell or reflects a subpopulation of rapidly dividing
endothelial cells remains uncertain. In FGFR1-expressing
endothelial cells (FGFR1/CD31) bFGF stimulated mito-
genesis, both in the absence and presence of VEGF. Addition
of bFGF to embryoid bodies particularly stimulates angio-
genesis in embryonic bodies by the length growth of vascular
structures, while the stimulatory effect of VEGF regards the
formation of a complex capillary plexus.16 Although embry-
oid bodies derived from stem cells that lack one or both
alleles of FGFR1 are still able to form endothelial cells and
vascular structures, the formation of hematopoietic progenitor
cells is impaired. Analysis of the mRNA expression in
FGFR1/ embryoid bodies showed a 50% increase of the
mesodermal marker brachyury at day 4, indicating a delayed
progression of differentiation as compared with their
FGFR1/ counterparts. After 8 days, when endothelial cells
and vascular structures had become developed, a relatively
normal development of the endothelial lineage in these
embryonic bodies was observed. However, a number of genes
involved in hematopoietic differentiation were highly sup-
pressed in the FGFR1/ embryoid bodies, including SCL/
Tal1, CD41, and the -H1 and GATA-1, two proteins
involved in development of erythrocytes. Indeed, at day 12
day virtually no expression of the leukocyte marker CD45
was seen in FGFR1/ embryoid bodies, in contrast to the
FGFR1/ ones. This indicates that the differentiation into
hematopoietic progenitor cells is severely impaired, and
suggests that FGF/FGFR1 signaling is required for this
differentiation.
These data are consistent with previous observations of
Faloon et al,7 who showed a considerable reduction of
VEGFR2, SCL/Tal1, -H1, and -major production in
FGFR/ embryoid bodies as compared with their FGFR1
wild-type counterparts. SCL/Tal1 is required for the commit-
ment of hemangioblasts into hematopoietic progenitor cell
differentiation.21–23,31 Therefore, it is likely that the absence
of SCL/Tal1 in FGFR1/ embryonic bodies is an important
contributor to the lack of hematopoietic differentiation. Over-
expression of SCL/Tal1 in FGFR1/ embryonic bodies may
resolve whether this is the only factor preventing hematopoi-
esis or whether other factors also contribute to this phenom-
Figure 1. Development of early vasculature in embryoid bodies.
EB indicates embryoid body; pcd, postcoidal day; LIF, leukemia
inhibitory factor.
Figure 2. Differentiation of hemangioblasts
into hematopoietic cells and endothelial cells.
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enon. Faloon et al7 indicated that in SCL/Tal1/ embryoid
bodies endothelial markers were elevated 2- to 4-fold, sug-
gesting preferential differentiation into the endothelial lin-
eage. This raises two questions. First, are the endothelial cells
differentiating directly from the primitive hemangioblast in
FGFR1/ and SCL/Tal1/ conditions identical in character-
istics as those deriving wild-type conditions from the defin-
itive hemangioblasts? Second, does (over)expression of SCL/
Tal1 reduce differentiation into the angioblast and endothelial
lineage, or is the increase in endothelial differentiation in
FGFR1/ and SCL/Tal1/ embryonic bodies merely caused
by the lack of transition into hematopoietic progenitor cells?
Other studies have shown that SCL/Tal1 deficiency causes
defects in endothelial growth and yolk sac vascularization,
indicating that this factor also contributes to proper endothe-
lial development.31,32 Apparently experimental conditions
may influence the degree to which endothelial development
occurs in this deficiency. Because replenishment of SCL/Tal1
in 3.5- to 4-day-old SCL/Tal1/ embryoid cells by Cre-lox–
mediated induction or viral transduction showed that the
function of hematopoietic and endothelial cells can be nor-
malized,31,33 it is likely that SCL/Tal1 deficiency causes
deflection of the hemangioblast differentiation into the direc-
tion of the angioblast lineage producing endothelial cells and
smooth muscle cells. A similar mechanism may occur in the
case of FGFR1 deficiency.
Although the studies of Magnusson et al15 and Faloon et al7
indicate that FGFR1 is dispensable for early vascular devel-
opment in embryoid bodies, this does not exclude that FGFR1
contributes to vascular development and angiogenesis. Sev-
eral lines of evidence support such a role. First, part of the
endothelial cells in the embryoid bodies and in the new
vasculature of teratomas does contain FGFR1. A considerable
part of these cells is involved in cell division. Whether this
expression is paralleled by effects of FGF/FGFR1 on cell
division or migration cannot be deduced from these experi-
ments. An alternative explanation might be that FGF/FGFR1
signaling reduces the vulnerability of endothelial cells for
apoptosis, as shown in vitro.34,35 It may be a general strategy
in development to enhance apoptosis vulnerability of cells
that make important steps in differentiation or morphogenic
patterning, to avoid improper growth. If FGF/FGFR1 signal-
ing would be able to overcome this vulnerability, FGF
signaling would act as a “permissive factor” in development.
Indeed, such a permissive role of FGF has been well
documented in neural stem cell differentiation where FGF has
a dual action maintaining the size of the progenitor pool by its
proliferative effects as well as stimulating proneural differ-
entiation by modulating signaling36 Given the involvement of
FGF/FGFR1 signaling in the process of differentiation of
many different cells, including cardiomyocytes, adipocytes,
bone cells, and hematopoietic cells and in patterning of
mesoderm and embryo vessels,7,15,37–39 this is a concept that
warrants further investigation. Such a concept may also
explain why the subpopulation of circulating progenitor cells
that contain FGFR1 may be particularly successful in differ-
entiating into an endothelial phenotype in adult man.40
Interestingly in the FGFR1/ embryoid bodies the lack of
FGFR-1 signaling resulted in an abnormal branching pattern
of the vasculature.15,16 Although these in vitro systems do not
completely reflect the normal embryonic or organ-specific
multicellular environment (embryoid bodies lack the polarity
of the embryo) and the precise state of differentiation of
endothelial cells, they underpin a potential role of FGF/
FGFR1 signaling in patterning of the vascular network. This
is in line with studies of Lee et al,29 who used a dominant-
negative truncated FGFR1 behind a CMV-promoter, which
was injected in the 9-day-old murine embryo, and becomes
expressed preferentially in vascular and endocardial endothe-
lial cells. The overexpression resulted in abnormal develop-
ment including incomplete branching of the vascular
network.29
The formation of a vascular network as well as mesoder-
mal development require coordination of cell signaling and
stepwise recruitment of cytokines in a temporally and spa-
tially coordinated manner. These processes warrant factors
that can change the cellular environment from a nonpermis-
sive one into a permissive milieu for such processes. The
current study of Magnusson adds another piece of the puzzle
to the concept that FGF/FGFR1 is not a conditional factor but
rather one of these permissive factors.
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